MMED
Fiscal year ends April Quarters are offset from the calendar — Q1 is May–Jul

MiniMed Group, Inc. is a medical technology company that develops, manufactures, and markets integrated solutions for the management of diabetes. The company serves patients with Type 1 diabetes and a subset of Type 2 diabetes patients who require intensive insulin therapy. Its product portfolio includes Automated Insulin Delivery (AID) systems, such as the MiniMed 780G, 770G, 740G, 720G, and 630G, which combine insulin pumps, continuous glucose monitoring (CGM) sensors, and Smart Dosing algorithms. Additionally, the company offers the MiniMed Go Smart Multiple Daily Injection (MDI) system, featuring the InPen smart insulin pen and compatible CGM sensors. MiniMed utilizes a dual-channel distribution approach in the United States, primarily through the durable medical equipment (DME) channel, and serves customers globally. The company’s technologies are prescribed by endocrinologists, diabetologists, nurse practitioners, physician assistants, and primary care physicians.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Medical Devices Homepage investors.minimed.com
Sector Healthcare IR page investors.minimed.com
Tags
diabetes management, insulin pumps, continuous glucose monitoring, automated insulin delivery, smart insulin pens, dosing algorithms, medical technology, MiniMed 780G, MiniMed 770G, MiniMed 740G, MiniMed 720G, MiniMed 630G, MiniMed Go, InPen, Simplera Sync, Instinct, Guardian, Smart Dosing, SmartGuard
Press page —

Metrics

Valuation  
Market cap $ 5.475B
Market cap (USD) $ 5.475B
P/E -14.98
PEG —
P/BV 1.51
P/S 1.77
P/OCF -27.79
P/FCF -13.04
Dividend yield —
Turnover / mcap —
Returns  
ROE -9.2%
ROI -9.9%
ROIC -4.2%
Profit margin -10.7%
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -70.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026
Revenue 3.102B
Net profit -333M
Free cash flow -420M

Figure FY 2026
Share price 14.92
P/FCF -9.98

Filed figures

Figure Apr 2023 Apr 2024 Apr 2025 Apr 2026
Balance sheet detail
Trade receivables (USD) — — 570M 200M
↳ YoY growth -64.9%
Lease liabilities (USD) — — 67M 53M
Cash and deposits (USD) 58M 54M 11M 298M
Intangible assets (USD) — — 132M 107M
Right-of-use assets (USD) — — 66M 52M
Cash flow detail
Operating cash flow (USD) — 41M 140M -197M
Purchases of property, plant and equipment (USD) — -148M -193M -223M
Change in inventories (cash effect) (USD) — 5M -19M -29M
Income taxes paid (cash effect) (USD) — 0.00 0.00 -2M
Share-based compensation (USD) — 38M 41M 46M
Free cash flow (OCF - PPE - intangibles) (USD) — -107M -53M -420M
Income detail
Research and development expense (USD) — 437M 436M 448M
Total comprehensive income (USD) — -114M -179M -297M
Comprehensive income to owners (USD) — -114M -179M -297M
Provision for credit losses (USD) — 22M 21M 28M
Credit cost ratio (credit losses / average receivables) (%) — — — 7.3%
Reported Jun 29, 2026 Jun 29, 2026 Jun 29, 2026 Jun 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

MiniMed Group, Inc. — Regulation FD Disclosure Bull 3 Bear 4 Guidance

On November 16, 2026, MiniMed Group, Inc. (“MiniMed”) announced that the U.S. Food and Drug Administration (the “FDA”) has cleared the MiniMed Fit™ patch pump, MiniMed’s first tubeless insulin pump, offering people with diabetes a new differentiated option that combines up to seven days of wear, a 300-unit insulin capacity, app control and proven SmartGuard™ technology. FDA clearance was received several months ahead of expectations and is expected to accelerate U.S. commercialization of this key product, which is now anticipated to launch in Spring 2027 in advance of the previously communicated timing of Summer 2027.

Given the FDA clearance of MiniMed Fit, MiniMed is expected to recognize a one-time charge in the third quarter of fiscal year 2027 related to the previously disclosed minimum payment of $162 million for the first two years following regulatory approval in the United States and commercial launch of the MiniMed Fit patch pump under its research and development agreement with affiliates of Blackstone Life Sciences Advisors L.L.C., which became an obligation of MiniMed in connection with its separation from Medtronic plc.

MiniMed Completes Separation from Medtronic Bull 0 Bear 0 M&A

NORTHRIDGE, Calif., Oct. 15, 2026 /PRNewswire / -- MiniMed (Nasdaq: MMED) today announced the completion of its separation from Medtronic plc ("Medtronic"; NYSE: MDT), marking its first day as a fully independent company.

MiniMed logo

"Today marks the completion of our separation from Medtronic and a significant milestone for MiniMed," said Que Dallara, Chief Executive Officer of MiniMed. "We are grateful to Medtronic for its partnership and support in reaching this point. As an independent company, we have the freedom to make the decisions we believe are right for our business and the people we serve, and the responsibility to see those decisions through. Our focus now is to put that independence to work and continue advancing what is possible in diabetes care."

As separately announced yesterday, Medtronic accepted an aggregate of 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 shares of MiniMed common stock. As a result, Medtronic no longer holds an equity stake in MiniMed. The exchange offer was 5.4x subscribed.

Full details of the results of the exchange offer are available in a separate press release issued yesterday by Medtronic. The exchange agent will promptly credit newly issued shares of MiniMed common stock in book-entry form to accounts maintained by the MiniMed transfer agent for tendering shareholders whose Medtronic ordinary shares were accepted in the exchange offer. Checks in lieu of fractional shares of MiniMed common stock will be delivered after the exchange agent has aggregated all fractional shares and sold them in the open market.

**About MiniMed
**MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.

**Forward Looking Statements
**This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to the expected effects on Medtronic and MiniMed of the exchange offer, the anticipated benefits of the exchange offer, Medtronic's and MiniMed's anticipated financial results, all other statements in this communication that are not historical facts, and other risks and uncertainties described in Medtronic's and MiniMed's periodic reports on file with the SEC including their most recent respective Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, the Registration Statement on Form S-4 filed by MiniMed in connection with the exchange offer, including the Prospectus forming a part thereof, the Schedule TO, and other exchange offer documents filed by Medtronic or MiniMed, as applicable, with the SEC. In some cases, you can identify these statements by forward-looking words or expressions, such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "looking ahead," "may," "plan," "possible," "potential," "project," "should," "going to," "will," and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. MiniMed undertakes no obligation to update forward-looking statements or any of the information contained in this press release.

SOURCE MiniMed

Prompts

MiniMed Group, Inc. (ticker MMED), listed in United States.

Company History

Date Change Detail
Aug 27, 2025 Renamed MDT Sub Holdings, Inc. → MINIMED GROUP, INC.
— Former tickers MMEDV

ETFs Holding MiniMed Group, Inc.

ETF Weight in ETF Shares Market value As of
MMID 1.09% 19,510 $ 395.273K Aug 31, 2026
FSCC 0.21% 37,884 $ 767.53K Aug 31, 2026
AAUS 0.17% 49,429 $ 880K Nov 18, 2026
AVSC 0.16% 270,198 $ 5.039M Nov 16, 2026
RESM 0.02% 48 $ 717.60 Jun 30, 2026
AVUS 0.00% 6,840 $ 127.566K Nov 16, 2026
AVSU 0.00% 82 $ 1,529.30 Nov 16, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
MMED canonical Common share — US nasdaq 19.47 USD 2026-09-30
MMEDV delisted Common share — US nasdaq — —